Cardiometabolic Disease
Effect of APOC3 Inhibition with Olezarsen on Coronary Atherosclerosis: Essence–TIMI 73b Imaging Study
Scientific Publications & Presentations
Built on decades of scientific leadership, Ionis continues to advance the understanding of disease through groundbreaking research and innovation. Explore select publications across our therapeutic areas and technologies to better understand the science behind our medicines and pipeline.
Showing 13-24 out of 66 results
Cardiometabolic Disease
Olezarsen Data Presented at the American College of Cardiology's 75th Annual Scientific Session
Other Medicines
Switching Long-Term Prophylaxis to Donidalorsen for Hereditary Angioedema: 1-Year OASISplus Results
Neurology
Salanersen Data Presented at the Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
Castro et al - Phase 1 interim results evaluating the safety tolerability pharmacokinetics and exploratory efficacy of salanersen for spinal muscular atrophy.pdf
Crawford et al - STELLAR Phase 3 Studies to Evaluate the Efficacy and Safety of Salanersen in Infants with Spinal Muscular Atrophy.pdf
Shieh et al - The SOLAR Study - Phase 3 Study to Evaluate the Efficacy and Safety of Salanersen in Participants Aged 15 to 60 Years with Spinal Muscular Atrophy.PDF
Other Medicines
Donidalorsen for hereditary angioedema: Long-term results from a 4-year, phase 2, open-label extension study
Other Medicines
Donidalorsen for Long-Term Prophylaxis of Hereditary Angioedema Attacks: Results from the OASISplus Open-Label Extension Cohort at Year 1
Cardiometabolic Disease
Pelacarsen and lipoprotein(a) apheresis in secondary prevention: the Lp(a)FRONTIERS APHERESIS trial
Neurology
Exploratory analyses of clinical outcomes from the BIIB080 phase 1b study in mild Alzheimer’s disease
Neurology
High-dose nusinersen for spinal muscular atrophy: a phase 3 randomized trial
Neurology
Long-Term Tofersen in SOD1 Amyotrophic Lateral Sclerosis
Cardiometabolic Disease
Olezarsen for Managing Severe Hypertriglyceridemia and Pancreatitis Risk
Neurology
A single-arm phase 2 trial of an investigational RNA therapeutic to complement factor B sefaxersen for treatment of IgA nephropathy